Reumatismo

Objective. Intra-articular injections of hyaluronic acid (HA) have been reported to alleviate pain, reduce disability, and improve joint function in glenohumeral osteoarthritis (GH-OA). This retrospective study aimed to evaluate the effectiveness of a HA-based formulation (Hyalubrix®) in reducing the pain of patients with GH-OA and improving both patient's shoulder functions and quality of life (QoL). Methods. Data collected during the standard clinical practice of the center was retrospectively analyzed. The Simple Shoulder Test (SST) questionnaire reported data on the patient's ability to perform daily activities; the Euro-Quality of Life Health Assessment (EQ-5D) collected evidence on QoL; and changes in pain were evaluated through the Visual Analog Scale (VAS). SST and EQ-5D scores were analyzed comparing baseline values with those at the last follow-up, while VAS was investigated for all the available visits. Continuous values were summarized as mean ± standard deviation, median, and 25-75th percentiles. Shapiro-Wilk test assessed normality, with significance set at p&lt;0.05, and no adjustments for multiple comparisons were made. Results. All scores showed a significant improvement: VAS decreased from 55.4±13.8 to 16.2±16.3 (p&lt;0.001), the SST increased from 38.0 to 65.5 (p&lt;0.001), as well as the EQ-5D (from 41.7 to 76.7; p&lt;0.001). Conclusions. GH-OA treatment with Hyalubrix® proved to be highly beneficial, leading to complete pain reduction in more than 50% of patients and a significant reduction in 27.5% of cases. This resulted in improved joint function and QoL.

L. Monti

E. Franchi

F. Verde

S. Sgherzi

F.M. Anghilieri

Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid- based injections (Hyalubrix&lt;sup&gt;®&lt;/sup&gt;) in patients with glenohumeral osteoarthritis

超声引导下关节内透明质酸注射（Hyalubrix®）治疗肩关节骨关节炎疗效的回顾性评估

The pain of osteoarthritis (OA) has multifaceted etiologies within and outside the joint. It is believed to be driven by both nociceptive and neuropathic mechanisms, as well as abnormal excitability in the pain pathways of the peripheral and central nervous system. Inflammation in the joint triggers a cascade of events that leads to peripheral sensitization, increased sensitivity of nociceptive primary afferent neurons, and hyperexcitability of the nociceptive neurons in the central nervous system. Pain receptors have been found in the synovium, ligaments, capsule, subchondral bone and surrounding tissues, with the exception of articular cartilage. The bone-related causes of pain in OA include subchondral microfractures, bone stretching with elevation of the periosteum due to osteophyte growth, bone remodeling and repair, bone marrow lesions, and bone angina caused by decreased blood flow and increased intra-osseous pressure. Central factors alter pain processing by setting the gain in such a way that, when a peripheral input is present, it is processed against a background of central factors that can enhance or diminish the experience of pain. As a complex phenomenon with a strong subjective component, pain can also be influenced by the nature of the underlying disease, personal predisposition (biological and psychological), and environmental and psychosocial factors. This review examines the current literature regarding the sources and mechanisms of pain in OA.

F. Salaffi

A. Ciapetti

M. Carotti

The sources of pain in osteoarthritis: a pathophysiological review

Objective. Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in rheumatoid arthritis (RA) patients. Methods. We recruited consecutive RA patients starting baricitinib or tofacitinib. At baseline, 4 and 12 weeks, we calculated disease activity [Disease Activity Score on 28 joints (DAS28), Clinical Disease Activity Index, Simplified Disease Activity Index], disease status [remission and low-disease activity (LDA)], percentage of patients achieving PASS, and the time to attain PASS. We assessed the impact of clinically relevant variables on PASS achievement by logistic regression analysis. Results. We enrolled 113 patients [98 (86.7%) females; median age 59.6 (interquartile range 16.9), median disease duration 144 (132) months]. 90 (79.6%) patients achieved PASS after 10 (8) days. A similar percentage of PASS achievers and non-achievers was in remission/LDA at weeks 4 and 12, but the reduction of disease activity was significantly greater in PASS achievers. All patients achieving Boolean remission at weeks 4 and 12 had achieved PASS within 4 weeks. The impact of Patients Global Assessment (PGA) on DAS28 was significantly greater in PASS non-achievers compared to PASS achievers; inversely, the impact of C-reactive protein was more relevant in PASS achievers. At multivariate analysis, pain and PGA were significantly associated with PASS. Conclusions. In our cohort, Jakinibs allowed an early achievement of PASS in a great percentage of RA patients. PASS is strictly dependent on PGA and pain and could suggest, early in the management of RA patients, therapeutic success.

C. Garufi

S. Mancuso

F. Ceccarelli

L. Caruso

C. Alessandri

M. Di Franco

R. Priori

V. Riccieri

R. Scrivo

S. Truglia

F. Conti

F.R. Spinelli

PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

转向患者视角：接受性症状状态在类风湿性关节炎患者早期实现——使用JAK抑制剂治疗

Juvenile dermatomyositis (JDM) is a rare chronic systemic inflammatory disorder with a highly variable clinical course. It is important to identify the patients at risk of developing more severe disease. However, based on the existing literature, there is a lack of data regarding predictors of poor outcomes. Obtaining knowledge about clinical and laboratory risk factors for disease progression and severity at an earlier stage of the disease could potentially lead to a better long-term prognosis for patients with JDM.

A Martins

S Ganhão

F Aguiar

M Rodrigues

I Brito

Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review

青少年皮肌炎不良结局的预测因素：我们了解多少？叙述性综述

To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD).

E Lubrano

A Armuzzi

S Scriffignano

C Felice

F M Perrotta

V Venerito

S Del Vescovo

R Ramonda

G Cassone

F Atzeni

R Caporali

F Conti

E Gremese

F Iannone

M Sebastiani

E G Favalli

The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease

外周脊柱关节炎的整体管理：关注炎症性肠病患者的关节受累

Takayasu arteritis and spondyloarthritis are two rheumatological diseases whose co-existence is well-documented in the literature. Data on the presence of inflammatory back pain in Takayasu arteritis without a diagnosis of spondyloarthritis, however, is scarce. Here, we present a 33-year-old man who was admitted to the emergency department with acute-onset chest pain associated with left carotidynia, carotid bruit, and left arm claudication, normal electrocardiogram and computed tomography angiographic features suggesting Takayasu arteritis, including stenosis and occlusion of the aorta and its branches. Two years prior, he had undergone a clinical work-up for an inflammatory back pain accompanied by alternating buttocks pain, morning stiffness lasting more than half an hour, and heel pain. HLA-B27 status and magnetic resonance imaging of the sacroiliac joints were both negative. He was prescribed non-steroidal anti-inflammatory drugs and was placed on adalimumab 40 mg SC every two weeks but had to switch to etanercept two months before his emergency admission due to supply issues. Oral prednisolone was initiated at a dose of 60 mg/day with symptomatic improvement in both his inflammatory back pain and his chest pain, but he had to be switched to methotrexate and infliximab due to steroid side effects. Inflammatory aortitis should be considered as a possibility during the assessment of inflammatory back pain to mitigate the risks of delayed diagnosis.

F.I. Gorial

N.I. Awadh

A. Al-Shakarchi

G. Al-Gburi

Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

大动脉炎表现为少见的炎性腰背痛：一例报告

Abbreviation
Journal Impact	1.27
Quartiles(Global)	RHEUMATOLOGY(Q4)

ISSN	0048-7449, 2240-2683
h-index	30

Publication Information	Publisher: Page Press Publications，Publishing cycle: ，Journal Type: journal，Open Access Journals: Yes
Basic data	Year of publication: 1985，Proportion of original research papers: 86.36%，Self Citation Rate:8.30%， Gold OA Rate: 93.83%
Average review cycle	网友分享经验：10 Weeks

Reumatismo

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid- based injections (Hyalubrix<sup>®</sup>) in patients with glenohumeral osteoarthritis

The sources of pain in osteoarthritis: a pathophysiological review

PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review

The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease

Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid- based injections (Hyalubrix<sup>®</sup>) in patients with glenohumeral osteoarthritis

Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review

The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease

PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report